Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab in pediatric NMOSD
NCT05549258Phase 2Recruiting
- Sponsor
- Amgen
- Start
- Jul 2023
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Amgen. Started Jul 2023; status: recruiting.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05549258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549258.